CN-680000-ME216-A3.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO. 3

AHCA Contract No. MED216, Amendment No. 3, Page 1 of 3

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency" and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended as follows:

1. Standard Contract, Section II., THE AGENCY AGREES, Sub-Section A., Contract Amount, the first sentence is hereby amended to now read as follows:

To pay for contracted services according to the conditions of Attachment I., Scope of Services, in an amount not to exceed $597,965.00, (an increase of $52,963.00), subject to the availability of funds.

2. Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1., Projects to be Completed by the Vendor, is hereby amended to now include Sub-Items c. through g., Project 2: Sickle Cell Disease Study.

c. Criteria for Florida Centers of Excellence for Sickle Cell Disease

1) The Vendor shall review at least five (5) existing Centers of Excellence (“Centers”) and identify any best practices that may support quality of health outcomes and health care value for Florida Medicaid recipients with sickle cell disease (“SCD”).

2) The Vendor shall determine criteria for the creation of Florida Centers of Excellence for Sickle Cell Disease with the purpose of increasing quality of health outcomes and health care value for Florida Medicaid recipients with

SCD.

3) The Vendor shall produce a report containing a summary of input from the SCD work group members on criteria for the potential creation of Florida Centers of Excellence for Sickle Cell Disease.

4) The FMSQN workgroup may use the report and findings to share with our Colleges of Medicine leaders and State leadership as applicable and as approved by the Agency.

d. Provider Education for Treating Patients with Sickle Cell Disease

1) The Vendor shall assess existing Florida provider education courses and shall propose topics for other modules based on identified gaps in existing provider education courses.

2) Upon Agency approval of proposed topics, the Vendor shall create modules that address gaps and expand on existing provider education courses.

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFADocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

ATTACHMENT I

EXHIBIT A

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Amendment No. 3, Page 2 of 6

e. Preferred Drug List for Treating Patients with Sickle Cell Disease

1) The Vendor shall obtain and evaluate the current Medicaid fee-for-service preferred drug list (PDL), as well as non-covered drugs, for medications that are proven to benefit patients with SCD for efficacy, including indications for treatment, variety of agents, dosing, schedule, supply number, refill number and frequency, and the appropriateness of a variety of drug utilization management controls.

2) The Vendor shall make recommendations to the Agency for other medications, including new therapies.

f. Performance Measures for Treating Patients with Sickle Cell Disease

1) The Vendor shall produce a report containing a summary of existing performance measures with the goal to improve the health care for individuals with SCD.

2) The Vendor shall conduct an assessment to identify the performance measures that are most likely to effectively evaluate and track quality of care indicators including patient experience, prevention of disease complications and SCD health outcomes.

3) The Vendor shall provide a summary of any gaps the group identifies in the existing measures, including information that explains why the group feels new proposed performance measures are important, if applicable.

g. External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

1) The Vendor shall identify and summarize at least 3 external funding opportunities. The summary shall include the following elements, at a minimum:

• Name of the external funding organization/entity and website for applying;

• Brief summary of the funding opportunity;

• Due date of the application for the funding opportunity;

• Qualifications to determine a potential lead/principal investigator;

• Contact information for any individual(s) interested in serving as a lead/principal investigator; and,

• Contact information for any individual(s) interested in applying for external funding – not to be restricted to SCD project workgroup members and/or SCD project researchers.

3. Attachment I, Scope of Services, Exhibit A, Deliverables and Financial Consequences, is hereby amended to include Contract Year 2 (State Fiscal Year 2022 – 2023) deliverables eight (8) through twelve (12) as follows:

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFADocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Amendment No. 3, Page 3 of 6

8.

DELIVERABLE 8

Criteria for Florida Centers of Excellence for Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/10/2023

AMOUNT

$9,755.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 8 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

9.

DELIVERABLE 9

Provider Education on Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/28/2023

AMOUNT

$10,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.d.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 9 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent (10%) of the total invoiced amount.

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFADocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Amendment No. 3, Page 4 of 6

11.

DELIVERABLE 11

Performance Measures for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.f.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/21/2023

AMOUNT

$8,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.f.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 11 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent (10%) of the total invoiced amount.

10.

DELIVERABLE 10

Preferred Drug List for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.e.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/05/2023

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.e.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 10 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent (10%)

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFADocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Amendment No. 3, Page 5 of 6

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

12.

DELIVERABLE 12

External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.g.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/19/2023

AMOUNT

$5,208.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.g.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 12 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent (10%)

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFADocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

DELIVERABLES AND FINANCIAL CONSEQUENCES

AHCA Contract No. MED216, Amendment No. 3, Page 6 of 6

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

IN WITNESS WHEREOF, the Parties hereto have caused this six (6) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC.

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1DocuSign Envelope ID: E24F9966-0C17-4880-8D09-FF9613921EFA

SVP USF Health, Dean, Morsani College of Medicine

1/6/2023 | 11:31 EST

Dr. Charles Lockwood

DocuSign Envelope ID: F4EFC295-1FF0-44DD-ACA5-83F6863F69A1

1/6/2023

Deputy Secretary of Medicaid

Tom Wallace